VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 25, 2016) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE:NPH)(NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that it has been recognized in the 2016 TSX Venture 50 as the top performing Clean Technology & Life Sciences Company. The Company ranked number one in the sector.
"We are honored to be recognized by the TSX Venture given the competitive environment occupied by innovative companies," said Mr. Arun Nayyar, CEO of Vanc. "I am proud of what our team at Vanc has been able to accomplish over the past two years and we look forward to sharing further progress in 2016."
About TSX Venture 50™
The 2016 TSX Venture 50™ is a ranking of strong performers on TSX Venture Exchange. These companies have shown results in key measures of market performance. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. On average, these companies have delivered a return of 77% in 2015. The shares of these companies also enjoy a liquid market, with a total of 3.0 billion shares trading over the course of 2015.
On behalf of:
Vanc Pharmaceuticals Inc.
Arun Nayyar, CEO, anayyar@vancpharm.com
"We are honored to be recognized by the TSX Venture given the competitive environment occupied by innovative companies," said Mr. Arun Nayyar, CEO of Vanc. "I am proud of what our team at Vanc has been able to accomplish over the past two years and we look forward to sharing further progress in 2016."
About TSX Venture 50™
The 2016 TSX Venture 50™ is a ranking of strong performers on TSX Venture Exchange. These companies have shown results in key measures of market performance. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. On average, these companies have delivered a return of 77% in 2015. The shares of these companies also enjoy a liquid market, with a total of 3.0 billion shares trading over the course of 2015.
On behalf of:
Vanc Pharmaceuticals Inc.
Arun Nayyar, CEO, anayyar@vancpharm.com